First-in-class mitogen-activated protein kinase (MAPK) p38a: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing properties

Autor: Tulapurkar, Mohan E., Shirey, Kari Ann, Lugkey, Katerina, Luo, Wendy, Lal, Ritu, Galan, Adam, Mahmoud, Omar, McClean, Nathaniel, Thangaraju, Kiruphagaran, Cericola, Daniel, Lewis, Daniel, Murphy, William A., Fletcher, Steven, MacKerell, Alexander D., Jr, Vogel, Stefanie N., Shapiro, Paul, Hasday, Jeffrey D.

Publikováno v: In The Journal of Pharmacology and Experimental Therapeutics July 2024

Progress in the development of kinase inhibitors for treating asthma and COPD.

Autor: McClean N; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States., Hasday JD; Department of Medicine, Division of Pulmonary Medicine, University of Maryland School of Medicine, Baltimore, MD, United States., Shapiro P; Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, United States. Electronic address: pshapiro@rx.umaryland.edu.

Publikováno v: Advances in pharmacology (San Diego, Calif.) [Adv Pharmacol] 2023; Vol. 98, pp. 145-178. Date of Electronic Publication: 2023 May 03.